Author

N. P. Martin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

D. L. Brody· 2 shared T. J. Esparza· 2 shared C. J. Tucker· 1 shared C. Z. Chen· 1 shared D. Esposito· 1 shared D. Li· 1 shared D. Mahapatra· 1 shared E. Castro· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

D. L. Brody

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Evaluation of endogenous and therapeutic 25-hydroxycholesterols in murine models of pulmonary SARS-CoV-2 infection

M. B. Fessler, J. Madenspacher, P. J. Baker, K. L. Hilligan, E. Castro, J. Meacham, S.-H. Chen, R. F. Johnson, N. P. Martin, C. J. Tucker, D. Mahapatra, M. Cesta, K. D. Mayer-Barber

This study evaluates the antiviral and inflammatory effects of 25-hydroxycholesterol and its metabolite in murine SARS-CoV-2 models, finding no significant antiviral activity and potential pro-injury effects.

bioRxiv · Sep 12, 2022 · PreprintImmunology

Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19

T. J. Esparza, Y. Chen, N. P. Martin, H. Bielefeldt-Ohmann, R. A. Bowen, W. D. Tolbert, M. J. Pazgier, D. L. Brody

This study shows that nebulized NIH-CoVnb-112 nanobody reduces weight loss, viral burden, and lung pathology in Syrian hamsters infected with SARS-CoV-2.

bioRxiv · Nov 10, 2021Biochemistry

Camel nanobodies broadly neutralize SARS-CoV-2 variants

J. Hong, H. J. Kwon, R. Cachau, C. Z. Chen, K. J. Butay, Z. Duan, D. Li, H. Ren, T. Liang, J. Zhu, V. P. Dandey, N. P. Martin, D. Esposito, U. Ortega-Rodriguez, M. Xu, , M. Ho

The paper isolates two camel nanobodies that broadly neutralize SARS-CoV-2 and its variants, showing therapeutic potential in mice.

bioRxiv · Oct 27, 2021Immunology

High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme

T. J. Esparza, N. P. Martin, G. P. Anderson, E. R. Goldman, D. L. Brody

This study identifies nanobodies that block SARS-CoV-2 spike protein interaction with ACE2, showing high affinity and stability after nebulization.

bioRxiv · Jul 24, 2020Biochemistry